3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
6
Biopsy
6
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
4
Cisplatin
3
Carboplatin
3
tazemetostat
2
selpercatinib
2
larotrectinib
2
erdafitinib
2
entrectinib
2
ensartinib
2
cabozantinib
2
Topotecan
2
Temozolomide
2
Surveys and Questionnaires
2
Radiation
2
LY3023414
2
Gemcitabine
2
Etoposide
2
Cyclophosphamide
2
ulixertinib
1
tipifarnib
1
pegfilgrastim
1
palbociclib
1
olaparib
1
niraparib
1
mirdametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
amino-acid, glucose, and electrolyte solution
×
90 days
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled